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Efflux pump activity potentiates the evolution of
antibiotic resistance across S. aureus isolates
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The rise of antibiotic resistance in many bacterial pathogens has been driven by the spread of
a few successful strains, suggesting that some bacteria are genetically pre-disposed to
evolving resistance. Here, we test this hypothesis by challenging a diverse set of 222 isolates
of Staphylococcus aureus with the antibiotic ciprofloxacin in a large-scale evolution experiment.
We find that a single efflux pump, norA, causes widespread variation in evolvability across
isolates. Elevated norA expression potentiates evolution by increasing the fitness benefit
provided by DNA topoisomerase mutations under ciprofloxacin treatment. Amplification of
norA provides a further mechanism of rapid evolution in isolates from the CC398 lineage.
Crucially, chemical inhibition of NorA effectively prevents the evolution of resistance in all
isolates. Our study shows that pre-existing genetic diversity plays a key role in shaping
resistance evolution, and it may be possible to predict which strains are likely to evolve
resistance and to optimize inhibitor use to prevent this outcome.
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nfections caused by antibiotic resistant bacteria are currently
estimated to cause ~700,000 deaths per year, and this mor-
tality rate is predicted to increase to 10 million per year by
20501. Given this threat, resistance has been identified as one of
the most important challenges to human health by a wide variety
of national and international bodies, including the WHO, the G8
and the IMF. To solve this crisis, we require new antimicrobials to
treat infections caused by resistant pathogens and new approa-
ches to predict and prevent the spread of resistance in pathogen
populations2–4.
The increase in antibiotic resistance in many pathogens has
been driven by the spread of a relatively small number of very
successful antibiotic resistant lineages5–10. One explanation for
this pattern is that these successful lineages are simply those that,
by chance, successfully acquire rare antibiotic resistance genes by
mutation or horizontal gene transfer11,12. Alternatively, it is
possible that some strains of bacteria are more likely to evolve
resistance than others, for example because they have an elevated
mutation rate13, or because they carry ‘potentiator’ genes that
open up new genetic paths to evolving resistance14,15. If so, it may
be possible to identify strains of bacteria that are at high risk of
evolving resistance to antibiotics, and to change antibiotic usage
to prevent this outcome and associated treatment failure16.
In this paper, we investigate genomic drivers of evolvability
using comparative experimental evolution. In this approach,
many bacterial ‘parental’ strains are challenged with a common
selective pressure using controlled and highly replicated in vitro
evolution experiments. Following the trajectory of replicate
selection lines after antibiotic exposure makes it possible to
estimate the evolvability of each strain, and downstream pheno-
typic and genomic analyses are used to characterize evolved
populations14,17. This approach makes it possible to address three
separate questions: (i) Does the ability to evolve antibiotic resis-
tance differ between bacterial strains? (ii) What are the under-
lying mechanisms of resistance evolution? (iii) How does genome
content determine the rate and mechanisms of resistance
evolution?
We applied this approach at a very large scale by challenging
a diverse collection of 222 parental strains of Staphylococcus
aureus with ciprofloxacin using a highly replicated selection
experiment. Parental strains were sampled from a large col-
lection of nasal carriage and bacteraemia isolates of S. aureus
collected at hospitals in Oxford and Brighton, UK18, and were
chosen to capture a diverse set of clonal-complexes of human-
associated S. aureus. We chose to focus on ciprofloxacin
because the evolution of ciprofloxacin resistance has played a
key role in the success of MRSA lineages19, and has been
associated with poor clinical outcomes for patients infected
with CC22 S. aureus20.
Results
Evolution of ciprofloxacin resistance across S. aureus. We
serially passaged 12 replicate populations of 222 parental strains
of S. aureus into fresh culture medium supplemented with the
clinical breakpoint concentration of ciprofloxacin (1 mg l−1) for
5 days and recorded bacterial density over time (Fig. 1a, b and
Supplementary Fig. 1). All of the parental strains were cipro-
floxacin sensitive according to EUCAST clinical breakpoint (MIC <
1mg l−1) and we initiated our populations with an inoculum
small enough (~3 × 105 cells) to virtually guarantee that no pre-
existing resistance mutations were present at the outset of the
experiment (cipR mutation rate 5.1 × 10−9 per cell division, 95%
CI= [3.7 × 10−9, 6.7 × 10−9]). Conventional antibiotic treatment
strategies rely on using large doses of antibiotics to clear pathogen
populations, and this simple experimental design seeks to capture
this by creating a scenario in which populations must either
evolve resistance or face extinction.
Bacterial population density declined at the start of the
experiment due to the bactericidal effects of ciprofloxacin and
the population bottlenecking imposed by serially passaging
cultures. However, population density eventually recovered in a
subset (1075 of 2664; 40%) of cultures, suggesting that these
populations had expanded due to the de novo evolution of
ciprofloxacin resistance during our experiment. To test this idea,
we measured the ciprofloxacin MIC for 83 populations that
recovered, each derived from a different parental strain
(Supplementary Fig. 2). All evolved populations had an MIC >
1mg l−1, demonstrating that population recovery was driven by
the evolution of resistance. Therefore, we measured the
evolvability of ciprofloxacin resistance in the parental strains as
the fraction of populations that survived until the end of the
selection experiment. Our selection experiment revealed striking
variation in evolvability across S. aureus; for example, resistance
always evolved in 24 strains, whereas resistance never evolved in
39 strains (Supplementary Fig. 3a).
All else being equal, strains with a higher initial resistance to
ciprofloxacin should have a greater opportunity to evolve
resistance to a fixed dose of ciprofloxacin. For example,
populations of strains with higher initial resistance should decline
more slowly under ciprofloxacin treatment, allowing more
opportunity for the emergence of novel ciprofloxacin resistance
mutations21. To test this hypothesis, we measured the growth of
the parental strains across a fine gradient of ciprofloxacin
concentrations, and used growth data to calculate a ciprofloxacin
MIC and IC50 for each strain. Although the parental strains were
all ciprofloxacin sensitive with respect to the EUCAST clinical
breakpoint (i.e. MIC ≤ 1 mg l−1), we found subtle and quantita-
tive variation in initial resistance between the parental strains—
for the rest of the manuscript we refer to this variation as the
intrinsic resistance of the parental strains (Supplementary Fig. 4).
Evolvability increased with intrinsic ciprofloxacin resistance,
and intrinsic resistance accounts for 27% of the variation in
evolvability between parental strains (Pearson’s correlation r=
0.55, N= 222, P= 2e−18; Supplementary Table 1). One inter-
esting insight from this analysis is that small differences in
intrinsic resistance between strains were associated with large
differences in evolvability. For example, using a logistic regression
we estimated that a strain with IC50= 0.12 mg l−1 (median across
all strains) would have a 0.36 probability of evolving resistance.
Decreasing or increasing the IC50 by only 0.1 mg l−1 (equivalent
to 1/10 of the selection dose) would change the predicted
evolvability to 0.10 or 0.72, correspondingly (Supplementary
Fig. 3b, Supplementary Table 1, 2). In contrast, there was no
correlation between the resistance (i.e. IC50) of evolved popula-
tions and their parental strains, suggesting that the mechanisms
of high level resistance that evolved during the selection
experiment were independent of the intrinsic resistance of the
parental strains (Pearson’s correlation r=−0.03, N= 83, P=
0.7989).
It is also possible that some strains of S. aureus are genetically
pre-disposed to evolving resistance, for example because they
have a high mutation rate13,22, or alternative mechanisms for
evolving resistance14. To test if strains belonging to different
lineages of S. aureus evolved resistance at different rates, we
grouped all parental strains into 14 non-overlapping clusters
based on genetic distance estimated from whole genome data (see
“Methods”)23,24. We chose to focus on these clusters, rather than
pre-defined clonal complexes , because some clonal complexes,
such as CC1 and CC8 were very prevalent in our parental strains,
whereas other clonal complexes were represented by only few
strains, making it difficult to accurately quantify variability within
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and between clonal complexes (Supplementary Tables 3 and 4).
This sampling bias was not deliberate; rather, our pool of parental
strains was skewed towards dominant ciprofloxacin-sensitive
strains found in the UK.
Evolvability varied significantly between clusters, and among-
cluster variation accounted for an additional 16.6% of the
variation in evolvability (Fig. 1c, Supplementary Tables 1–3).
This effect was largely driven by the fact that clusters with high
levels of intrinsic resistance also had high evolvability (Supple-
mentary Fig. 5). However, we found significant variation in
evolvability between clusters after correcting for intrinsic
resistance, implying that some strains of S. aureus have elevated
evolvability that cannot be explained simply by high intrinsic
resistance (likelihood ratio test χ2= 187.13, d.f.= 13, P= 5.94e
−33). For example, strains from cluster 10, which is made up
CC398, evolved resistance at a much higher rate than would have
S. aureus strains, N = 222
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been expected based on their intrinsic resistance (Supplementary
Table 5, cluster 10, Supplementary Fig. 5).
Genomic basis of resistance evolution. One simple hypothesis to
explain variation in evolvability between clusters is that some
strains might have access to evolutionary paths to ciprofloxacin
resistance that are not accessible to others14,15. To test this
hypothesis, we sequenced the genome of a single evolved popu-
lation from each of 121 parental strains that spanned the spec-
trum of evolvability.
The canonical mechanism for S. aureus to evolve ciprofloxacin
resistance is by point mutations that alter ciprofloxacin targets,
including topoisomerase IV (grlA, grlB) and DNA gyrase (gyrA,
gyrB)25,26. Most (106/121; 88%) evolved populations had a single
mutation in these established targets (grlA, n= 100; grlB, n= 6;
Fig. 2a) and the most common SNPs in evolved populations, such
as grlA E84K and grlA S80F/Y, are often found in ciprofloxacin
resistant clinical isolates.
We found very few mutations (n= 36; =0.30 mutations per
population) outside of these known ciprofloxacin resistance
genes, and two lines of evidence suggest that the majority of these
mutations were neutral with respect to ciprofloxacin-mediated
selection. Strong selection for resistance consistently leads to
parallel evolution in key genes involved in antibiotic
resistance14,27–30, but we found no evidence of parallel evolution
in genes other than grlA and grlB. Second, we compared the ratio
of replacement to silent mutations in proteins across the genome,
under the assumption that positive selection leads to an excess of
Fig. 1 Experimental evolution of ciprofloxacin resistance. a Maximum-likelihood phylogeny of S. aureus strains included in this study. The tree was
constructed using a whole-genome alignment of 222 strains mapped to the S. aureus MRSA252 reference genome and corrected for recombination.
b Population growth during experimental evolution. Five heatmaps show optical density (λ= 595) of bacterial populations at the end of each transfer. The
optical density varies from low (no growth, OD595 < 0.08, black) to high density (high growth, OD595 > 1, bright yellow). In each heatmap, the columns
correspond to 12 replicate populations, and the rows correspond to 222 strains. c The correlation of population survival and intrinsic resistance in 14
phylogenetic clusters. Each data point represents one strain where population survival is the proportion of replicate populations that evolved resistance,
and intrinsic resistance is IC50 (half growth inhibition dose) of a parental strain. Colour and shape for each strain indicate MLST (multilocus sequence
type). An open circle is shown when MLST could not be determined. 222 strains were assigned to 14 phylogenetic clusters based on a genetic distance
matrix obtained from the phylogenetic tree in (a). The black curves show a model fit for the logistic regression between survival and intrinsic resistance
across all 222 strains (the same for all clusters, GLM: χ2= 393.93, d.f.= 1, residual d.f.= 220, p < 2.2e−16), and the red curves show cluster-specific
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Fig. 2 Genomic basis of evolved ciprofloxacin resistance. a Resistance mutations in the evolved S. aureus populations identified by whole-genome
sequencing (N= 121). The panels shows the identified mutations in gyrA, grlB and grlA (red) or the amplification of norA gene (blue). The populations are
ranked by the evolvability of their parental strains shown as barplots on top of the panel. bMutation rate in high and low evolvability strains. We measured
the mutation rate to rifampicin resistance using a Luria-Delbruck fluctuation test. Lines in the figure connect pairs of high and low evolvability strains (N=
11 pairs). Two-sided Wilcoxon signed-rank test: W= 0.8311, P= 0.8311, N= 12. c Copy number across sites spanning the 7239 bp region that is amplified
in ST3535 and ST291 evolved strains. Copy number was calculated by summing the number of reads per site, normalized by the mean sequencing depth
across all sites mapping to the ST291 reference genome, and smoothed using a generalized additive model. Gene annotations are shown below: yellow=
ISSau1 transposases; blue= norA.
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replacement mutations that alter protein function relative to what
we would expect from spontaneous mutation alone31. Replace-
ment mutations (n= 33) were more common than silent (n= 3)
mutations, but the excess of replacement mutations was only
marginally greater than the neutral expectation (Ka/Ks= 2.80;
N= 36; P= 0.095), suggesting that many non-target site muta-
tions were neutral mutations that hitch-hiked to high frequency
with adaptive resistance mutations. The key insight from this
analysis is that resistance usually evolved through SNPs in well-
defined ciprofloxacin targets, demonstrating a common evolution-
ary path to resistance in both high and low evolvability strains.
Given the key role of SNPs in resistance, variation in the
underlying mutation rate might drive differences in evolva-
bility between strains, as is the case in M. tuberculosis13. To test
this hypothesis, we measured the mutation rate of pairs of high
and low evolvability strains sampled across the S. aureus
phylogeny. Mutation rate varied substantially across strains,
but high evolvability was not associated with an elevated
spontaneous mutation rate (Fig. 2b, two-sided Wilcoxon
signed-rank test; P= 0.83, N= 12). Furthermore, we found
no evidence of an increased substitution rate in high
evolvability strains during the selection experiment (Supple-
mentary Fig. 6, W= 273.5, P= 0.16, two-sided Mann–Whitney
U test). Although mutation rate varies between ancestral
strains, we found no evidence that high evolvability was
associated with hypermutator strains.
One of the most conspicuous cases of high evolvability is the
ST291 strains from clonal complex CC398. All eight strains from
this group evolved resistance at a high rate, but only 1/8 evolved
populations had a classical resistance SNP. Instead, the evolved
populations from ST291 lineage carried 3–24-fold amplifications
of a ~7 kb region of the chromosome that includes norA (Fig. 2c),
an efflux pump that contributes to the intrinsic resistance of S.
aureus towards ciprofloxacin32,33. Although the extent of norA
amplification was impressive, the resistance of evolved popula-
tions with norA amplification (median MIC= 8 mg l−1; n= 7)
was only marginally higher than the resistance of populations
with topoisomerase substitutions (median MIC= 4 mg l−1; N=
69; two-sided Wilcoxon rank sum test W= 138.5, P= 0.0474).
The amplified region is flanked by two homologous copies of
an IS30 family transposase (ISSau1), suggesting that amplification
could have been caused by either transposition to different sites in
the genome or tandem amplification driven by the homologous
copies of ISSau134. To discriminate between these possibilities, we
used ISmapper35 to search for new transposon insertion sites in
the chromosome. We did not detect any new ISSau1 insertion
sites in the evolved populations, demonstrating that tandem
amplification, which can occur at a much higher rate than point
mutations36,37, drove the increase in norA copy number. While
the ISSAu1 transposon is also found in a few strains outside of
CC398 (Supplementary Fig. 7), we speculate that norA amplifica-
tion is not observed in those strains because norA is not flanked
by nearby copies of ISSAu1, as determined by re-analysing the
genomes of parental strains.
Given the uniform selective pressure imposed by our
experiment, we were surprised by the extent of variation in
ISSau1-mediated gene amplification. All of the evolved popula-
tions with gene amplification had increased ciprofloxacin MIC,
but ciprofloxacin resistance was not correlated with norA copy
number (Pearson’s correlation r=−0.5733, N= 7, P= 0.1374),
suggesting that selection for resistance does not explain variation
in the extent of norA gene amplification. Gene amplification is
often associated with fitness costs37, suggesting that selection to
minimize the cost of resistance may drive variation in gene
amplification. However, we found no detectable costs of gene
amplification, suggesting that selection for high growth rate did
not shape variation in norA copy number (Supplementary Fig. 8,
two-sided Wilcoxon signed-rank test, N= 16, P= 0.3125).
In summary, whole genome sequencing allowed us to uncover
the mechanistic basis of evolved ciprofloxacin resistance in
(114/121= 94%) of evolved populations. Most strains of S. aureus
evolved ciprofloxacin resistance via canonical mutations in DNA
topoisomerase, albeit at different rates. In contrast, strains from
CC398 evolved resistance at a very high rate via a different
mechanism involving amplification of the norA efflux pump gene
mediated by a lineage-specific IS element. We found no evidence
of parallel evolution in the remaining seven strains, suggesting
that they acquired less common mechanisms of ciprofloxacin
resistance (see a list of mutations in Supplementary Data 2).
Transcriptomic insights into high evolvability. Sequencing the
genomes of evolved populations does not provide any obvious
insights into why the rate of evolution of resistance by
target alteration varied so widely among non-CC398 strains. One
possible solution to this problem is that ‘potentiator’ genes that
alter the fitness effects of topoisomerase mutations may underpin
variation in evolvability in non-CC398 strains. To search for
candidate potentiator genes, we sequenced the transcriptomes of
14 pairs of high and low evolvability parental strains after
exposure to ciprofloxacin. These pairs of parental strains were
sampled from different parts of the phylogeny by choosing pairs
of strains which are closely related (based on genetic distance) yet
showed a striking difference in their evolvability (survival ≥ 9/12
and ≤1/12, Supplementary Table 6). The goal of this paired design
was to identify genes that are consistently associated with high
evolvability across a range of genetic backgrounds. Gene expres-
sion was always measured after 1.5 h of exposure to 1 mg l−1 of
ciprofloxacin to match the conditions of the evolution experi-
ment, and our transcriptome experiment did not measure basal
gene expression in the absence of ciprofloxacin stress38.
In total, we identified 179 genes that were differentially
expressed between high and low evolvability parental strains
(Fig. 3a; Supplementary Data 3). Ciprofloxacin induces the SOS
response, which provides both protection against ciprofloxacin
and increased mutagenesis39, making SOS expression an obvious
candidate mechanism to potentiate resistance evolution38. The
SOS regulon was expressed in all strains, but there was no
difference in the expression level of SOS regulated genes between
high and low evolvability strains (Supplementary Table 7).
Instead, overexpressed genes in high evolvability strains were
enriched for metabolic functions, while genes that were over-
expressed in low evolvability strains were enriched for DNA
repair and nucleotide biosynthesis, which is consistent with the
DNA damage caused by ciprofloxacin treatment (Supplementary
Data 4). The only overexpressed gene in high evolvability strains
with a known role in resistance was norA, suggesting that this
efflux pump might play a very general role in the evolution of
ciprofloxacin resistance across S. aureus (Fig. 3b).
Testing the ability of norA to potentiate resistance evolution.
To directly test the role of norA expression in evolution, we
cloned norA into RN4220, a genetically tractable model strain
with low evolvability. Overexpressing norA from its native pro-
moter marginally increased ciprofloxacin resistance, as we would
expect given the established role of this pump in exporting
ciprofloxacin from the cytoplasm. However, this effect was very
weak, and norA overexpression was not actually sufficient to
increase the MIC of RN4220 above the clinical break-point
concentration of 1 mg l−1 (Fig. 4a, Supplementary Table 8). To
test the role of elevated norA expression in evolution, we repeated
our evolution experiment by passaging 40 replicate cultures of
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strain RN4220 in ciprofloxacin supplemented media under basal
or elevated levels of norA expression. In contrast to the subtle
effect of norA overexpression on ciprofloxacin resistance, we
found that norA overexpression had a dramatic effect on popu-
lation survival under sustained ciprofloxacin treatment, trans-
forming RN4220 from a low evolvability (9/40 populations) to
high evolvability (40/40 populations) strain (Fig. 4b; Supple-
mentary Tables 9, 10).
Despite the recent progress in S. aureus forward genetics
methods40, it remains a difficult task to test the importance of
norA across many S. aureus strains. To overcome this problem,
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Fig. 3 Gene expression analysis. a Plotted points show the average difference (high evolvability−low evolvability) in gene expression between 14 pairs of
high and low evolvability strains. Gene expression was measured after 1.5 h of exposure to ciprofloxacin (1 mg l−1) and each point represents a gene in the
MRSA252 transcriptome (the number of genes is n= 2047). Significantly differentially expressed genes are coloured red (p < 0.05, two-sided Wald tests)
and norA is coloured blue. P-values were adjusted using Benjamini-Hochberg method. b The expression of norA in low and high evolvability strains. The
read counts for the norA gene were normalised by sequencing depth. Pairs of strains are connected with a line (the number of pairs was N= 14). Two-sided












































































Fig. 4 The role of norA in resistance evolution. a The effect of norA overexpression on ciprofloxacin resistance. Resistance was measured in the RN4220
cells overexpressing norA from vector pRMC2 under a native promoter (red), compared to an pRMC2 empty vector control (grey) and a vector-free control
(blue). N= 3 independent cultures were used per treatment per concentration. Dose-response curves show model fit from the analysis presented in
Supplementary Table 8. b The effect of norA overexpression on the evolution of ciprofloxacin resistance. Optical density (λ= 595) was measured for five
daily transfers with 1 mg l−1 of ciprofloxacin in RN4220 cells overexpressing norA from the pRMC2-norA vector (red), cells with the empty pRMC2 vector
(blue) and the cells without the vector (grey). N= 40 independent cultures were used for each type of cells. Statistical analysis in shown in Supplementary
Table 10. c The effect of reserpine on intrinsic resistance. Intrinsic resistance to ciprofloxacin (IC50, mg l
−1) was determined for a representative set of
27 strains in the presence (y-axis) or absence of 33 µM reserpine (x-axis) (N= 5 per dose/reserpine combination). Two-sided Wilcoxon signed-rank test:
W= 308, d.f.= 26, p= 0.003. d Evolvability was determined for the same set of 27 strains with 33 µM reserpine (y-axis) or without reserpine (x-axis).
Evolvability was measured as the probability of population survival after 5 serial transfers at 1 mg l−1 of ciprofloxacin (N= 16 replicate populations for each
strain/reserpine combination). Two-sided Wilcoxon signed-rank test: W= 226, N= 27, p-value= 0.000128.
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strains (N= 27) in the presence and absence of reserpine, a
chemical inhibitor of NorA41 (Supplementary Fig. 9a, Supple-
mentary Table 11). Reserpine treatment reduced intrinsic
resistance to ciprofloxacin (Fig. 4c). Although this impact of
reserpine on intrinsic resistance was evident, it translated on
average into less than twofold reduction (IC50/IC50 RES= 1.31
±0.47 s.d.; MIC/MICRES= 1.52 ± 0.49 s.d.), with a stronger
inhibition of strains with high intrinsic resistance (Spearman’s
correlation ρ= 0.76, p= 7.4e−06, n= 27), suggesting that this
higher intrinsic resistance is at least partly based on the efflux of
ciprofloxacin.
To understand the evolutionary consequence of norA expres-
sion more broadly, we repeated our evolution experiment by
passaging 16 replicate cultures of these 27 strains in media
containing ciprofloxacin, or both ciprofloxacin and reserpine
(Supplementary Fig. 9b; Supplementary Tables 12, 13). The
overall effect of reserpine was to suppress the evolution of
resistance (two-sided Wilcoxon signed-rank test: W= 226,
N= 27, P= 0.000128). Reserpine had little effect on low
evolvability strains, but it almost completely suppressed the
evolution of ciprofloxacin resistance in high evolvability strains,
including strains from CC398 (Fig. 4d). Collectively, these results
show that norA expression modulates the intrinsic resistance of S.
aureus to ciprofloxacin and potentiates the subsequent evolution
of clinically relevant levels of resistance. These findings provide a
simple explanation for the positive correlation between intrinsic
ciprofloxacin resistance and evolvability that occurs in S. aureus
(Fig. 1).
Evolutionary consequences of norA expression. The most
obvious effect of norA expression is to provide protection
against ciprofloxacin. This protective effect of norA could
accelerate the evolution of resistance by providing populations
with more time to generate resistance mutations until popu-
lation extinction42,43. To test the plausibility of this mechan-
ism, we measured the population dynamics of strain RN4220
under ciprofloxacin treatment (Fig. 5a). As expected, increased
norA expression reduced the rate of population decline under
ciprofloxacin treatment. However, the magnitude of this
effect was marginal—norA overexpression simply delayed the
onset of ciprofloxacin-induced cell mortality by ~1 h. This
weak effect of norA overexpression on cell viability further
highlights the fact that this efflux pump makes a small con-
tribution to the intrinsic resistance of S. aureus to high doses of
ciprofloxacin (i.e. 1 mg l−1; Fig. 4a). Importantly, it is very
difficult to reconcile this marginal effect of norA on cell via-
bility with the massive effect of norA overexpression on evol-
vability (Fig. 4b), suggesting that norA expression does not
accelerate evolution by increasing the rate of appearance of
resistance mutations.
The appearance of a ciprofloxacin resistance mutation in a
population does not guarantee that a population will successfully
evolve resistance, because stochastic processes can lead to the
extinction of small populations of resistant mutants, for example
during population bottlenecks44. All else being equal, mutants
with a high fitness upon antibiotic exposure should be more likely
to successfully expand their populations and cause populations to
evolve elevated resistance. To test the impact of norA expression
on fitness, we measured the growth rate of RN4220 carrying key
ciprofloxacin resistance SNPs under basal and elevated levels of
norA expression (Supplementary Fig. 10). Elevated norA expres-
sion did not increase growth rate in wild-type RN4220, which is
consistent with our previous ciprofloxacin susceptibility assays
(Fig. 4a). In contrast, increased norA expression led to large
increases in growth rate in ciprofloxacin resistant mutants,
demonstrating positive epistasis between target alteration and
antibiotic efflux (Fig. 5b).
norA expression could increase the fitness benefit provided by
resistance mutations in the presence of ciprofloxacin by reducing
the fitness costs of topoisomerase substitutions and/or increasing
the protective effect of topoisomerase mutations. To test this
hypothesis, we measured the growth of ciprofloxacin resistant
mutants under basal and elevated levels of norA expression across
a range of ciprofloxacin concentrations (Fig. 5c). Elevated norA
expression did not change the growth rate of resistant mutants in
the absence of antibiotics (two-sided paired t-test: t= 0.42009, P
= 0.6825, N= 12, Supplementary Fig. 10a), providing further
evidence that the expression of this pump has marginal effects on
fitness per se (see Fig. 4a and Supplementary Fig. 8). In contrast,
we found that elevated norA expression dramatically increased
the ability of grlA mutants to grow at high concentrations of
ciprofloxacin (i.e. 1 mg l−1, two-sided paired t-test: t=−18.712,
P= 1.09e−09, N= 12). In other words, positive epistasis occurs
because ciprofloxacin efflux mediated by norA and altered
topoisomerase structure (i.e. grlA) interact synergistically to
increase resistance to high doses of ciprofloxacin without
imposing any additional fitness burden.
Identifying variants associated with high evolvability. In order
to systematically search for genetic variants associated with high
evolvability, we carried out a genome-wide association study
(GWAS) to test for associations between core-genome SNPs and
evolvability across the strains used in this study (Supplementary
data 5). The GWAS analysis showed that 16.3% of variation in
evolvability can be explained by genetic variability across strains
(Supplementary Fig. 11). However, after controlling for multiple
testing, the GWAS failed to identify any SNPs that show a sig-
nificant association with high evolvability.
Given the strong association between norA and evolvability, we
then focused more closely on variants that are likely to be
associated with norA expression and function. All of the strains
used in this study are predicted to carry a functional copy of norA
(i.e. no pre-mature stop codons or frameshift mutations). In line
with previous work45, we found that the norA coding sequence is
polymorphic, and we identified polymorphisms in a previously
characterized norA promoter region46–48. However, the P values
associated with these polymorphisms are 1000 times higher than
the conservative significance threshold used in our GWAS
analysis, suggesting that these associations are true negatives.
Moreover, we failed to identify any norA variants associated with
high evolvability through manual inspection of our data.
The expression of norA is known to be repressed by the mgrA
transcription factor46,49,50, and two lines of evidence from our
transcriptome experiment suggest that mgrA plays a role in
evolvability. First, mgrA was overexpressed in low evolvability
strains (two-sided Wald test: log2 fold-change= 0.885, standard
error= 0.206, t=−4.305, adjusted p= 0.005597, Supplemen-
tary data 3). Second, we found a negative correlation between
mgrA and norA transcript levels across 12 of the 14 pairs of high
and low evolvability strains (Supplementary Fig. 12, exact
binomial test P= 0.00091, N= 14), suggesting that mgrA
represses norA in low evolvability strains. Although this
relationship between norA and mgrA is clear at a qualitative
level, the quantitative correlation between mgrA and norA
transcript levels is weak (Supplementary Fig. 12), suggesting that
other regulatory genes and/or post-translational modification of
MgrA play important roles in mediating norA expression49–51.
Interestingly, mgrA is highly conserved, and we only identified
two polymorphic sites in the strains used in our study.
These polymorphisms showed no evidence of association with
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17735-y ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:3970 | https://doi.org/10.1038/s41467-020-17735-y | www.nature.com/naturecommunications 7
evolvability in our GWAS (P values > 105 above conservative
threshold), potentially providing evidence that the connection
between mgrA and evolvability is complex.
Discussion
We found that the rate and mechanisms of evolution of cipro-
floxacin resistance vary dramatically across the diversity of S.
aureus, an important human pathogen (Figs. 1, 2). Studying the
evolution of resistance at this broad scale using a combination of
genomic and transcriptomic approaches allowed us to identify
lineages with high evolvability and genes that potentiate the
evolution of resistance, implying that it is possible to predict
the evolution of resistance from genomic data. Remarkably, a
single efflux pump gene (norA) plays a key role in accelerating the
evolution of ciprofloxacin resistance, either by increasing resis-
tance directly, as in the high evolvability CC398 lineage, or by
increasing the benefit provided by classical ciprofloxacin resis-
tance mutations that alter DNA topoisomerase.
NorA is a narrow-spectrum efflux pump that is known to
contribute to the intrinsic ciprofloxacin resistance in S. aureus,
but has not previously been linked to clinically relevant levels of
resistance32,41,52,53. High evolvability strains of S. aureus show
elevated levels of norA expression (Fig. 3), and overexpressing
norA in a lab strain dramatically increases evolvability (Fig. 4b) by
increasing the protective effect of ‘classical’ ciprofloxacin resis-
tance mutations in grlA (Fig. 5b, c). Inhibiting NorA in clinical
isolates leads to a marginal loss of intrinsic resistance (Fig. 4c)
and a massive reduction in evolvability (Fig. 4d), suggesting that
variation in norA expression creates a strong association between
intrinsic resistance and evolvability across the diversity of
S. aureus (Fig. 1).
Interestingly, positive epistasis has been found between cipro-
floxacin resistance SNPs and mutations that increase drug efflux
in Gram-negative bacteria54–57, suggesting that our findings may
help to explain the evolution of ciprofloxacin resistance across a
broad spectrum of bacterial pathogens where ciprofloxacin
resistance has emerged as an important clinical problem, such as
E. coli and P. aeruginosa. More generally, our findings suggest
that more attention should be given to understanding interactions
between resistance mutations and ‘background’ genetic variation
that can epistatically modify the fitness effects of canonical
resistance mutations14,30.
Although we have succeeded in linking norA expression to
evolvability, we were not able to determine the underlying genetic
basis of high evolvability outside of CC398. GWAS analysis has
promising potential to uncover the genetic basis of bacterial traits,
such as high resistance58 or virulence24, but this approach was
unable to uncover any associations between SNPs and high
evolvability. On the one hand, this lack of significance could be
explained by the fact that high evolvability is driven by SNPs that
are unique to individual lineages of S. aureus, in much the same
way as lineage-specific IS elements potentiate the rapid evolution
of resistance in CC398. Alternatively, it is possible that our
analysis simply lacked the statistical power needed to uncover
SNPs that are associated with high evolvability, perhaps as a result
of limited recombination in S. aureus59. The negative correlation
between the expression of the mgrA repressor and evolvability
suggests that mgrA-mediated repression of norA expression helps
to constrain evolvability, and an important goal for future work
will be to understand the connection between genetic variation,
transcriptional regulation and evolvability in pathogenic bacteria.
Our study included a number of strains from clonal complex
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Fig. 5 The mechanism of norA potentiation. a Exponentially growing cells were exposed to 1 mg l−1 of ciprofloxacin and viable cells counts were estimated by
plating on TSB agar. Four treatments were compared: (i) norA overexpression= red solid line, (ii) norA overexpression and reserpine (33 μM) inhibition=
orange solid line, (iii) empty vector control= grey line, and (iv) no vector control= blue line. In addition, cell density was measured in treatments (i)
and (ii) without ciprofloxacin (red dash-dotted line and orange dash-dotted line, correspondingly). For each time-point, six independent replicates per
treatment were measured (with the exception of the pRCM-norA cells in ciprofloxacin at 0 h which had N= 5). The lines show model fit for polynomial
regression (F23, 191= 622.6, p-value < 2.2e−16). Post-hoc comparisons are shown in Supplementary Table 14. b Growth rate of grlA mutants with or
without norA overexpression. We estimated the growth rate of the RN4220 wild type (WT) and three independently obtained mutants carrying each grlA
substitution in the presence of 1 mg l−1 of ciprofloxacin. Growth rate in cells carrying pRMC2-norA (red) or cells without the vector (blue) was determined
using growth curves shown in Supplementary Fig. 10b. Black horizontal lines show the mean growth rate of independent cultures (N= 6 per mutant/
treatment combination for A116E, E84K, S80F and S80Y, N= 11 for WT pRMC2-norA and N= 12 for WT no vector). Paired two-sided t-test comparing the
means in the mutants with and without pRMC2-norA: t= 11.958, d.f.= 11, p= 1.206e−07. Two-sided t-test comparing pRMC2-norA and no vector control
in WT: t= 0.96281, d.f.= 12.136, p= 0.3544. c Representative dose-response experiments for grlAmutants. Red lines show mean optical density with norA
overexpression, and blue lines show mean density without overexpression. Black arrow shows the concentration used during experimental evolution. Five
independent cultures were used per mutant/treatment/concentration. The results for all mutants are shown in Supplementary Fig. 10a. The difference of
means between pRMC2-norA and no vector cells at 1 mg l−1 for all mutants was tested using two-sided paired t- test: t=−18.712, P= 1.09e−09, d.f.= 11.
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(n= 7) and ST3535 (n= 1). The ST398 strains belong to the
human-associated lineage of ST39860 and they evolved via
mutations in grlA. The ST291 strains are genetically quite dif-
ferent from ST398 and represent a separate lineage within
CC39861; they are usually associated with humans62, but more
recently isolated from livestock63,64. These ST291 strains (and the
related ST3535 strain) rapidly and repeatedly evolved in response
to ciprofloxacin by ISSau1-mediated tandem amplification of
norA34, allowing them to increase ciprofloxacin resistance with-
out any detectable fitness cost. This is perhaps surprising, given
that the largest amplifications increased genome size by about 200
kb, which is equivalent to a ~7% increase in genome size. How-
ever, a number of other studies have found evidence that S.
aureus can acquire novel DNA, such as plasmids and SCCmec
elements, without any additional detectable fitness burden65,66.
More generally, the high copy number of ISSau1 in
CC398 suggests that gene amplification may be an important
mechanism of adaptation to novel environments, such as new
host species and antimicrobials67.
Whole-genome sequencing of bacterial pathogens is funda-
mentally transforming clinical microbiology68,69, and a key
challenge for this field is to exploit the wealth of data provided by
genomic sequences to better understand bacterial pathogenesis
and epidemiology3,23,24,70. By uncovering the link between gen-
otype and evolvability, it should be possible to use pathogen
genomic data to help predict the likelihood that resistance will
evolve during antibiotic treatment and to alter treatment strate-
gies accordingly. For example, our work suggests that cipro-
floxacin should be used cautiously to treat infections caused by
CC398 (and in particular ST291), due to the high risk of de novo
evolution of resistance. Outside of CC398, measuring the intrinsic
ciprofloxacin resistance of clinical isolates could be used in con-
junction with phylogenetic data obtained from genome sequen-
cing (Fig. 1) to predict the risk of resistance evolution during
treatment. For example, several clusters of strains in Fig. 1c have
low evolvability given their intrinsic resistance, making these
strains good candidates for ciprofloxacin treatment. Although we
have focused on ciprofloxacin resistance in S. aureus, it should be
possible to use experimental evolution and genomics to predict
the risk of resistance evolution for other pathogen/drug combi-
nations. This approach should be particularly useful to predict the
evolution of resistance to novel antimicrobials prior to their
introduction into clinical use3,71.
Understanding the genetic basis of evolvability also opens up
the possibility of using novel therapies to prevent the evolution of
resistance. For example, we have shown that using an efflux pump
inhibitor can prevent the evolution of resistance by blocking an
important evolutionary path to low costs resistance (see also
ref. 14). Recent work has shown that efflux pumps can also
accelerate resistance evolution by increasing the mutation rate72
or facilitating the acquisition of plasmids73, suggesting that efflux
pump inhibitors may have promising potential to suppress the
evolution of resistance74 for a large number of combinations of
pathogen and antibiotic.
Methods
Media and reagents. 96-well flat-bottom plates (Nunc, 260860) and Mueller-
Hinton 2 medium (MH2 medium, Sigma-Aldrich, 90922) were used for culturing
S. aureus, measuring antibiotic resistance and performing all evolution experi-
ments. Tryptic Soy Broth (TSB medium; Sigma-Aldrich, 22092) was used for
preparation of competent cells, for selecting transformed clones and for growing
S. aureus prior to DNA isolation. Incubation was performed at 37 °C and 225 rpm
orbital shaking inside a MaxQ 8000 shaking incubator (Thermo Fisher).
Ciprofloxacin (Sigma, 17850) was dissolved in water (5 mgml−1) and stored at
−20 °C. The other reagents used in this study were chloramphenicol (25 mgml−1
in ethanol, Acros Organics, 227920250), ampicillin (50 mgml−1 in water, Sigma,
A1593), kanamycin sulfate (25 mgml−1 in water, Fisher Chemicals), rifampicin
(50 mgml−1 in DMSO, Millipore, 557303), reserpine (10 mgml−1 in DMSO,
Sigma-Aldrich, 83580).
S. aureus strains. In total, 222 strains of S. aureus were collected from colonized
and infected patients in Oxford and Brighton, as previously described18. To ensure
that these isolates were clonal, the strains were streaked out on TSB agar plates. A
single colony was picked to inoculate overnight culture in TSB broth. The over-
night cultures of 222 strains were mixed with glycerol to a final concentration of
15% v/v and stored at −80 °C.
Measuring intrinsic resistance by broth microdilution. Intrinsic resistance was
determined for 222 strains by exposing five replicate cultures per strain to 8 doses
of ciprofloxacin (>8800 cultures in total). The strains were handled in five batches
with up to 60 strains per batch. Five replicate plates were included for each batch/
dose combination, and each plate contained only one replicate of each strain. In
order to minimize the effect of well location, five different strain layouts were
created by randomization. As a result, every strain was exposed to a given cipro-
floxacin concentration in five different plates and at five different well locations. To
control for contamination, limit excessive evaporation and avoid an edge effect, 36
wells on the edge of each 96-well plate did not contain bacteria.
The strains were recovered from −80 °C stock by growing overnight cultures
for 22 h, diluted 1:100 and randomized across five 96-well plates using a Precision
XS automatic pipetting station (BioTek). The resulting master plates were used for
transferring 10 µl of bacteria to assay plates containing 190 µl of MH2 broth with
ciprofloxacin. The assay plates were placed into the incubator for 22 h. After
incubation was completed, optical density was measured at OD595 using a Synergy
2 plate reader (BioTek).
OD595 values were used to estimate the MIC (minimal inhibitory
concentration) and perform a dose-response analysis. A concentration was
considered inhibitory if 3/5 replicate cultures did not reach a cut-off value of 0.08
OD595 including a blank. The median blank value was 0.042 OD595 (s.d.= 0.003),
however higher values were occasionally observed due to dust, excessive
evaporation, etc. Two assay plates were excluded from the analysis because of
unusually high variation in control wells (batch 3, dose= 0.1, replicate plate 5, and
batch 4, dose= 0.025, replicate plate 4). In the remaining dataset, only 2/6406
control wells had OD595 > 0.08.
For the dose-response analysis, a non-linear 4-parameter model was fitted:
f xð Þ ¼ cþ
d  c
1þ exp½b ´ log xð Þlog eð Þð Þ
;
where c is te lower asymptote (i.e. response variable at complete inhibition), d is the
upper asymptote (uninhibited growth), e is an inflection point equivalent to a half
growth inhibition dose (IC50) and b is a slope of the curve at the inflection point.
Parameter c was fixed at 0.08 to be consistent with the cut-off value, the remaining
3 parameters were estimated separately for each strain by fitting dose response
curves using the drc package in R75. The standard errors for IC50 were obtained
using the coeftest function from the package lmtest The dose response curves were
also used to calculate the area under a curve (AUC) using the trapz function in the
pracma package.
Experimental evolution of resistance. The evolvability of 222 ciprofloxacin-
sensitive strains (MIC ≤1 mg l−1) was measured by exposing each strain to 1mg l−1
for 5 daily transfers. For each strain, 12 replicate populations were included,
amounting to more than 2600 bacterial populations, which were transferred daily in
96-well plates. Prior to the experiment, replicates were distributed across the plates
so that each plate had a maximum of one replicate of any strain (except for six
plates which had two replicates for a set of 30 strains). For convenience, the strains
were handled in sets of up to 60 strains. For each set of strains, three-randomized
plate layouts were generated to assign strain locations within a plate. Each rando-
mization layout was used for only four replicate plates. As a result, any given strain
had replicate cultures located in 12 plates and in four different well locations (or in
six plates for the set of 30 strains mentioned previously). Wells at the plate edges
(rows A and H, and columns 1 and 12) were used for blank measurements and as
contamination controls.
The strains from −80 °C stock were grown overnight in 200 µl of MH2 (a single
culture per strain, five 96-well plates in total). After 22 h of incubation, each plate
was used to inoculate three fresh plates by transferring 20 µl of bacteria to 180 µl of
MH2. This step was simultaneously used to randomize the locations of strains
within plates and was performed using a BioTek Precision XS automatic pipetting
station. The resulting 15 plates contained three replicate cultures per strain and had
unique strain layouts. After 20 h at 37 °C, the cultures were transferred again to
fresh plates with MH2 and returned to the incubator. After the third recovery
transfer, 10 µl of culture was inoculated into MH2 medium containing 190 µl
of 1 mg l−1 of ciprofloxacin. Each culture was used to establish four replicate
populations resulting in 12 populations per strain. The plates were incubated for
22 h until the next transfer. In total, five transfers were performed in MH2 medium
with ciprofloxacin. At the end of each transfer, the optical density at OD595 was
measured. By transfer 5, most populations had either gone extinct or evolved
resistance and had a high density (more than 90% of surviving populations had an
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OD595 > 0.5). At this point, one more transfer without ciprofloxacin was performed
and the evolved populations were frozen in −80 °C in 15% glycerol.
Populations were considered to have survived if they had an OD595 > 0.08
(including blank) by transfer 5. Only 2/1942 control populations had an optical
density above 0.08, indicating a detectable but very low error rate due to
experimental artefacts and contamination. In the final dataset, evolvability was
defined as the proportion of survived populations per strain, ranging from 0/12
to 12/12.
To determine whether intrinsic resistance is a good predictor for evolvability, a
generalized linear model was fitted with a binomial family of distribution of errors.
Numbers of survived and extinct populations per strain were used as a response
variable (via the logit link function) and IC50 as a continuous covariate. In order to
control for a lineage effect on evolvability, each strain was assigned to one of 14
phylogenetic clusters. In particular, the cluster package in R was used to perform
PAM-clustering algorithm (“partition around medoids”, https://cran.r-project.org/
package=cluster). The performance of PAM-clustering was checked using the
silhouette diagnostic plots provided by the same package. Similar clustering
approaches have been used in previous studies to control for a lineage effect23,24.
Phylogenetic clustering was performed using a genetic distance matrix calculated
from a whole genome tree generated from sequence data mapped to MRSA252.
Cluster identities and their interaction with the IC50-covariate were added to the
model as fixed predictors. The emmeans package in R was used to test whether
cluster-specific effects differed significantly from the effects calculated for the
overall sample.
Ciprofloxacin resistance of evolved populations was determined by broth
microdilution method. Evolved populations were selected to maximize
phylogenetic diversity and variation in evolvability. Each population was derived
from a different parental strain (except strain ERR418532 for which two
populations were included). The growth of five replicate cultures for 83 evolved
populations was assayed across eight different concentrations of ciprofloxacin,
ranging from 0 to 32 mg l−1. The assays were performed in two blocks using five-
randomized plate layouts. MIC, IC50, and AUC was calculated using OD595 after
22 h of incubation.
DNA extraction and sequencing. DNA was extracted from one representative
evolved population for a subset of strains. In this subset, almost all the strains
which had an evolvability ≤3/12 (n= 48) or ≥ 9/12 (n= 44) were included. Eight
strains were excluded because they either failed to grow or the DNA concentration
was too low for sequencing. In addition, one evolved population for a repre-
sentative subset of strains with evolvability ranging from 4/12 to 8/12 (n= 29) was
included, resulting in a total selection of 121 evolved strains.
Strains were re-grown from −80 °C stock in 2 ml of TSB. Cells were collected by
centrifuging for 5 min at 5000 rpm and re-suspended in enzymatic digest buffer
(20 mM Tris-HCl, 2 mM EDTA, 1.2% Triton-X100, 0.03 mgml−1 lysostaphin
(Sigma-Aldrich, L7386), 25 mgml−1 chicken egg lysozyme (Sigma-Aldrich,
62970)). After 2–4 h of incubation at 37 °C to digest the cell wall, DNA was
extracted using DNeasy Blood & Tissue kit (Qiagen) following the manufacturer’s
protocol for Gram-positive bacteria. The integrity of genomic DNA was checked
on 0.9% agarose gel and the concentration was measured using a QuantiFluor
dsDNA Kit (Promega).
All parental strains were previously sequenced76 using an Illumina HiSeq 2000
platform (San Diego, CA, USA) and downloaded from the European Nucleotide
Archive Sequence Read Archive (study accession number: PRJEB5261). Evolved
strains were sequenced using an Illumina HiSeq 4000 platform with 150 base pair
(bp) paired-end reads at the Oxford Genomics Centre (Wellcome Centre for
Human Genetics, University of Oxford, Oxford, UK). Sequencing of evolved strains
yielded a mean coverage of 302x.
Sequencing reads from both the parental and evolved strains were trimmed
using Trimmomatic v0.3677. Leading and trailing bases were trimmed if the
Phred quality score was less than 20 and a 4-base wide sliding window was used
to cut reads when the average quality per base dropped below 15. Any read less
than 50 bp long was dropped. Sequences were mapped to the ST36 reference
strain MRSA252 (GenBank accession no. BX571856.1) using Stampy v1.0.3178,
with an expected substitution rate of 0.01. Single nucleotide polymorphisms
(SNPs) were called using the SAMtools v1.779 mpileup command, with the
following command line options: -F 0.002 -g -t DP -t SP, and the bcftools v1.780
call command with the following command line options: -m -O v -M -P 0.001 -p
0.5. All SNPs supported by fewer than 5 reads or by more than twice the mean
sequencing depth (calculated across all sites in the genome) were filtered from
the consensus FASTA sequence, which was generated using the bcftools
consensus command. Non-unique regions in the reference genome were
identified by self-self BLAST analysis of the reference with a word size of 28,
using the megablast algorithm in BLAST v2.5.081. Such regions represented
5.93% of the genome and were filtered from the consensus FASTA sequence for
each strain. Any base with a heterozygous call under a diploid model was also
filtered. Sequences were assembled into de novo contigs for each genome using
SPAdes v3.11.1 with the -careful mode turned on82. Multi-locus sequence typing
was performed on the assemblies using the S. aureus MLST website (https://
pubmlst.org) sited at the University of Oxford83.
Phylogenetic analysis of full parental sequence dataset. After mapping to the
MRSA252 reference genome, genome sequence data were used to construct a
maximum likelihood phylogenetic tree in RAxML v8.2.984, using the GTRCAT
model of nucleotide substitution. Branch lengths were corrected for recombination
using ClonalFrameML85, with a transition/transversion rate ratio (kappa) value of
4.04. This value of kappa was estimated from four independent analyses of subsets
of the data (n= 50) in PhyML v 3.3.2017010586.
Determination of evolved SNPs. Sequence assemblies for the parental strains
were annotated using Prokka 1.12-beta87. Snippy v4.0-dev2 (https://github.com/
tseemann/snippy) and breseq v0.33.188 were used to identify SNPs between each
annotated parental genome and the sequence reads from its corresponding evolved
genome for 121 strains. Snippy uses bwa to align reads to a reference (here, the
assembled parental genome) and FreeBayes to call variants89,90. SNPs were
required to have a minimum read mapping quality of 60, minimum base quality of
30 and a minimum coverage of 30. A lower mapping coverage threshold (15) was
used for SNPs in ancestral isolates due to the lower depth at which these were
sequenced. Snippy does not call SNPs at sites with heterozygous genotypes, which
here represent diversity within the sequenced culture. This means that any minor
variants present in the parental population that subsequently rose to fixation in the
evolved population are reported as evolved SNPs by Snippy. As such, only those
SNPs reported by both Snippy and breseq, and located at sites without a hetero-
zygous call in the parental strain, were classified as evolved SNPs. In 15/121 strains,
no SNPs were identified in genes for established ciprofloxacin resistance targets
(topoisomerase IV, DNA gyrase, norA). 6/15 strains were ST291/ST3535, for which
resistance is inferred to be conferred by amplification of norA. Inspection of the
variant call format (VCF) file revealed that four of the remaining nine strains had
heterozygous calls at known ciprofloxacin resistance sites, suggesting that these
evolved populations represented a mix of resistant and susceptible clones. These
strains were, therefore, classified as resistant. No known resistance mechanism
could be identified in five strains.
Copy number estimation of amplified region. Sequence data were remapped to
the ST291 reference genome JP80 (GenBank accession no. AP017922.1) to obtain
sequence depth estimates for the flanking transposase genes (not present in
MRSA252). Copy number was estimated as the total number of good quality reads
mapping at each site, normalized by the mean depth across all sites in the mapped
genome.
Evolutionary analysis of norA. To explore genetic diversity of norA within the
dataset, BLAST was used to identify the norA gene and 250 bp region upstream of
norA in the sequence assembly for each parental strain. Sequences were aligned
using Muscle v3.8.31 and a maximum likelihood phylogenetic tree was constructed
in PhyML using an HKY85 model of nucleotide substitution. Tree topology
improvement was computed using nearest-neighbour interchange and subtree
pruning and regrafting, selecting the best from both searches. This analysis iden-
tified three genetically distinct clades within the phylogeny, from which clade-
specific consensus sequences were generated by taking the majority allele at each
site. All SNPs within the promoter region for each sequence relative to the
respective clade-specific consensus and occurring at the tips of the whole genome
phylogeny were tested for association with norA expression, where this was mea-
sured. Ten SNPs were identified in total, five of which were in strains with
expression data across all three clades in the norA phylogenetic tree.
Copy number estimation of ISSau1 in parental strains. Sequence data from all
parental strains were mapped to the JP02758_0628 transposase gene located at the
5′ end of the amplified region of the genome using Stampy. Depth of sequence
coverage at each site was calculated using the samtools depth program. Transpo-
sase copy number was estimated by normalizing the mean sequence depth across
all mapped sites by the mean sequence depth across all sites in the corresponding
genome mapped to MRSA252.
Mapping the genomic location of new copies of transposase gene. The
increase in transposase copy number can be a result of tandem amplification or
transposition to a different genomic location. To differentiate these two mechan-
isms, the location of the JP02758_0628 transposase gene was mapped in eight
parental and eight evolved strains, in which the transposase amplification was
detected. This analysis was carried out using ISmapper v2.0.135. ISMapper takes
unmapped paired reads, maps them to an IS element and, then, identifies pairs in
which only one read is mapped to the IS element (JP02758_0628). These partially
mapped pairs are assumed to be at the junction of a transposon and its genomic
neighbourhood, and later used to determine transposition sites within a reference
genome (JP80, GenBank accession no. AP017922.1). As a result, a consistent
pattern of JP02758_0628 locations was detected between ancestral and evolved
sequences, identifying no new transposition sites in the evolved strains and sup-
porting the hypothesis of tandem amplification.
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Genome-wide association study. A GWAS was carried out using the bugwas70
package in R91. bugwas uses a linear mixed model to test for phenotype associa-
tions with both SNPs and lineages, while controlling for relatedness between
samples. As input, bugwas requires a sequence alignment, phylogenetic tree and
phenotype data for each sample. While it is possible to perform a continuous trait
GWAS in bugwas, the evolvability phenotype was not normally distributed and
therefore a continuous trait model was not suitable for this dataset. As such, a
binary trait GWAS was performed by limiting the analysis to low (evolvability ≤2/
12) and high (evolvability ≥9/12) evolvability strains, encoding phenotypes as
either 0 or 1 respectively. All strains with intermediate evolvability estimates were
excluded from the GWAS analysis, leaving a dataset of 96 strains. A sequence
alignment for all strains was obtained by mapping the corresponding sequence data
to the MRSA252 reference genome (as described above). A phylogenetic tree was
constructed from this sequencing alignment in RAxML v8.2.984 using the
GTRCAT model of nucleotide substitution. 89,874 biallelic and 8,591 multiallelic
SNPs were tested for association with evolvability and annotated in bugwas using
the MRSA252 reference genome. P-values were calculated using a likelihood ratio
test and a Bonferroni correction was applied.
Transcriptome analysis of parental strains. RNA-Seq analysis was performed
using the RNA from 30 parental strains. Since differences in gene expression may
be confounded by phylogenetic relationship, especially between phylogenetically
distant strains, expression was measured for 15 pairs of closely related high and low
evolvability strains. First, 15 high evolvability parental strains (evolvability ≥9/12)
were chosen to maximize phylogenetic diversity. For each high evolvability strain,
the most closely related low evolvability strain (evolvability ≤1/12) was identified
(Supplementary Table 6). The strains were grown for 16 h overnight in MH2 broth
at 37 °C at 225 rpm, diluted 1:20 in a fresh pre-warmed MH2 and incubated for an
additional 1 h and 20 min until they reached a density of 0.160–0.170 OD595.
Ciprofloxacin was added to achieve a final concentration of 1 mg l−1. After 1.5 h,
the exposure to ciprofloxacin was stopped by spinning cells for 10 min at 7000 rpm,
decanting supernatant and re-suspending the cells in 200 µl of PBS. Finally, 500 µl
of RNA-protect Bacteria Reagent (Qiagen) was added and the cells were equili-
brated at room temperature for 5 min and then frozen at −80 °C. The cells in
RNA-protect solution were thawed, centrifuged for 10 min at 5000 rpm and
separated from the supernatant. Next, the cells were mixed with 100 µl of enzy-
matic digest buffer (30 mM Tris-HCl, 1 mM EDTA, 2 mg l−1 protease K (Thermo
Fisher), 3.25 mg l−1 lysozyme (Sigma-Aldrich, 62970) and 0.15 mg l−1 lysostaphin
(Sigma-Aldrich, L7386)), re-suspended by pipetting and incubated for 10 min at
room temperature with shaking. Three hundred and fifty microliters of RTL buffer
(containing 2-mercaptoethanol (Sigma-Aldrich, M3148)) was added and RNA
extraction was performed using RNeasy Mini Kit (Qiagen), following the manu-
facturer’s protocol and including the optional step of DNase I on-column digestion.
Elution was performed twice using the same volume of 50 µl of RNase-free water.
RNA concentration was determined using the QuantiFluor RNA System (Pro-
mega). Samples were sent to Oxford Genomics Centre (Wellcome Centre for
Human Genetics, University of Oxford, Oxford, UK), where rRNA depletion was
performed prior to sequencing using an Illumina HiSeq 4000 platform, generating
75 bp paired-end reads.
Initial principal component analysis identified a likely batch effect, affecting one
high evolvability strain. This strain and its low evolvability pair was removed from
subsequent analysis. Transcript quantification of the RNA-Seq data from the
remaining 14 pairs was performed using Salmon v0.11.3, which maps reads to an
indexed reference transcriptome (MRSA252; GenBank accession no. BX571856.1)
using quasi-mapping approach and an inbuilt correction for fragment-level GC
bias92. Indexing of the reference transcriptome removed sequence-identical
duplicate transcripts and used a kmer length of 31 bp. The DESeq2 library in R was
used to estimate gene counts and perform differential expression analysis93 in
Bioconductor, with the requirement of at least 1 read mapping to each gene for
every strain. Normalised norA transcript counts for individual strains were
obtained using the plotCounts function in the DESeq2 library in R.
To test whether genes in different KEGG pathways were up or downregulated in
high or low evolvability strains, a KEGG pathway enrichment analysis was carried
out using the kegga and topKEGG functions in the limma library in R. A false
discovery rate cutoff for differentially expressed genes of 0.05 was used. A given
KEGG pathway was considered to be significantly enriched when P < 0.05.
Mutation rate estimation (fluctuation test). Mutation rate was determined for
33 parental strains. These 33 strains were selected in the following way. First, 11
high evolvability strains (survival > 10/12) were chosen to maximize phylogenetic
representation. Second, each of these strains was paired to the closest low evol-
vability strain (survival ≤ 1/12). In addition, 11 strains representing CC398 (ST398,
ST291 and ST3535) were included. The strains were assigned to three experimental
blocks, ensuring a similar representation of high and low evolvability strains in
each block.
The strains were re-grown from −80 °C stock in 200 µl of MH2 medium. After
24 h of incubation, strains were subject to a bottleneck by diluting them 107 times.
The bottleneck step was required to remove any pre-existing low frequency
mutations. The diluted bacterial cultures were used to establish 16 replicate cultures
per strain in 1.2 ml deep well plates (Brand, 701340) with 300 µl of MH2 per well.
After overnight incubation at 37 °C, 5 µl were sampled from eight replicates,
diluted 107or 108 times and plated on TSB agar plates to estimate population
density. Two hundred microliters of overnight cultures from all 16 replicates per
strains were plated on TSB-agar plates containing 100 mg l−1 of the antibiotic
rifampicin. After 24 h, the TSB plates without antibiotic were photographed using a
ColonyDoc-It Imaging Station (UVP, Cambridge, UK). The plates with antibiotic
and containing rifampicin-resistant mutants were photographed after 48 h.
Colonies were counted in ImageJ94 using a custom script written in ImageJ macro
language.
The colony counts from both types of plates were imported into R. The
mutation rate was calculated using the rSalvador package in R, which provides a
maximum likelihood estimate of mutation rate under the Luria-Delbruck model
and accounts for variation in population density95. To compare mutation rates
between strains, a Wilcoxon signed rank test (paired, two-sided) was performed.
The effect of reserpine on ciprofloxacin resistance. To determine the effect of
the norA inhibitor reserpine on intrinsic resistance and evolvability, 27 parental
strains (out of 222) were chosen using the following algorithm. First, nine high
evolvability strains (survival >10/12) were selected in different parts of the phylo-
genetic tree. Then, for each high evolvability strain the closest low evolvability
strains was identified (survival ≤1/12). In addition, we included nine strains from
the high evolvability clonal complex CC398. This set of strains is a subset from the
33 strains used for measuring mutation rates. However, this set of 27 strains is
different from the set used in transcriptomic analysis (though, two sets are over-
lapping), because of different survival thresholds used for defining high and low
evolvability strains and because here we included CC398 strains.
The strains were recovered from −80 °C stock and re-grown for two transfers in
200 µl of MH2 broth. During the second transfers, strain layouts were randomized
on plates using a Precision XS automated pipetting station (BioTek). Five different
randomization layouts were used corresponding to five replicate cultures included
per dose/treatment combination. Half of the cultures were exposed to eight
different concentrations of ciprofloxacin, and half to the same antibiotic
concentration and 33 µM of reserpine. After 22 h of incubation, population growth
was measured using a plate reader (OD595).
A dose-response analysis was performed by fitting a 4-parameter model. The
dose-responses curves were used to estimate IC50. The effect of reserpine on IC50
was evaluated by using the function EDcomp from the R package drc (version 3.0-
1). In addition, IC50 was compared using a two-sided Wilcoxon signed-rank test.
The effect of reserpine on evolvability. To estimate the effect of efflux pump
inhibitor on evolvability, experimental evolution was performed by exposing S.
aureus strains to 1 mg l−1 of ciprofloxacin, either with or without 33 µM of
reserpine. The same 27 strains that were used for measuring the effect of reserpine
on intrinsic resistance were used here. For each strain, 16 replicates with reserpine
and 16 replicates without reserpine were included. Strain positions on plates were
randomized using four different plate layouts. The wells at the plate edges (i.e. rows
A and H and columns 1 and 12) were used as controls.
The strains from −80 °C stock were re-grown overnight. During the second
transfers, strain positions within the plate were randomized using an automated
pipetting station. Half of the populations were challenged with 1 mg l−1 of
ciprofloxacin, and the other half with 1 mg l−1 ciprofloxacin and 33 µM reserpine.
Every day, >800 populations were transferred to fresh medium containing the same
dose of ciprofloxacin and/or reserpine. Population growth was measured after each
transfer by reading optical densities (OD595) using a plate reader. The experiment
was completed after five transfers.
Due to incomplete solubility of reserpine in water, the optical density of MH2
with reserpine was slightly higher than without reserpine. The average increase in
optical density due to reserpine was 0.011 OD595, as estimated by comparing a
blank sample with and without reserpine (0.049 ± 0.002 and 0.060 ± 0.008,
correspondingly; median ± s.d.). Therefore, prior to analysis, measurements from
wells containing reserpine were corrected by subtracting 0.011. After applying the
correction, populations that reached a density greater than 0.08 OD595 were
considered to have survived. The difference in survival due to the presence/absence
of reserpine was analysed separately for each strain by performing a Fisher’s
exact test. The resulting p-values were adjusted using Holm–Bonferroni method
(n= 27).
Cloning norA into the pRMC2 expression vector and transformation. Vector
pRMC2 was obtained from Addgene (#68940)96. The pRMC2 was linearized with
EcoRI and KpnI restriction enzymes (NEB) and gel purified using the QIAquick
Gel Extraction Kit (Qiagen). The norA gene and a 69 bp upstream region was
amplified with PCR, using Phusion DNA Polymerase (NEB). The genomic DNA of
strain ERR418607 (ST398) was used as a template. The primers contained 5′-
overhangs and were designed for Gibson assembly (see Supplementary Table 15).
The linearized vector and the PCR product were assembled using NEBuilder HiFi
DNA Assembly Kit (NEB) and transformed into E. coli DC10B (BCCM, Belgium,
LMBP 9585). The clones were selected on LB plates with ampicillin (100 mg l−1),
screened using PCR and confirmed by Sanger sequencing (primers are listed in
Supplementary Table 15). The expression vector containing norA was transformed
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into S. aureus RN4220 (DSMZ, Germany, DSM 26309) by electroporation using
the protocol described in ref. 40. The S. aureus transformants were selected on TSB
agar plates with chloramphenicol (10 mg l−1) and verified by PCR and Sanger
sequencing.
norA overexpression experiments (resistance and evolvability to cipro-
floxacin). The effect of norA overexpression on ciprofloxacin resistance was
measured using the broth microdilution method. Although norA was cloned under
a tetracycline-inducible promoter, increased resistance was also observed without
adding the inducer. This is potentially because a native promoter was also cloned as
a part of the norA upstream region. Further induction of norA with an anhy-
drotetracycline inducer increased resistance but simultaneously affected RN4220
growth rate in the absence of the antibiotic. In order to avoid a negative effect of
high overexpression on bacterial fitness and the antimicrobial effect of anhy-
drotetracycline itself, we decided not use the inducer in all following experiments
and relied on the uninduced level of expression.
To assess the effect of norA overexpression on resistance, the growth of RN4220
cells carrying pRMC2-norA was compared with cells carrying an empty vector and
cells without vector. First, S. aureus strains were cultured overnight in MH2 (cultures
that contained the plasmid were supplemented with 10mg l−1 chloramphenicol). The
next day, cultures were adjusted to a density of 5 × 106CFUml−1 and inoculated into
MH2 medium containing 10 different doses of ciprofloxacin. After 22 h of incuba-
tion, optical densities were measured. Three replicate cultures were included per
dose/genotype combination. The effect of overexpressing norA was analysed using
a dose-response curve.
To measure the effect of norA overexpression on evolvability, the RN4220 cells
carrying pRMC2-norA or an empty vector pRMC2, and vector-free cells were
experimentally evolved for five transfers at 1 mg l−1 of ciprofloxacin. Prior to the
experiment, 40 colonies per genotype were selected to establish parallel cultures.
After 22 h of incubation in MH2 broth (cultures with the plasmid were
supplemented with chloramphenicol). Ten microliters of overnight culture were
inoculated to wells containing 190 µl of MH2 and 1mg l−1 of ciprofloxacin. The
cultures were transferred daily to a fresh medium with ciprofloxacin. Populations
that reached an optical density of 0.08 or higher by transfer 5 were considered to be
alive. To test the differences in evolvability between genotypes, Fisher’s exact test
was performed on the number of survived/extinct populations and p-values were
corrected using the Holm-Bonferroni correction.
Killing assay using ciprofloxacin (the effect of norA expression on survival).
To measure the effect of norA expression on cell survival during the exposure to
ciprofloxacin, a killing assay was performed including four ciprofloxacin treatments
(1 mg l−1) and two control treatments (no ciprofloxacin). The ciprofloxacin
treatments were: (i) the RN4220 cells overexpressing norA, (ii) the RN4220 cells
overexpressing norA with 33 μM reserpine (NorA inhibitor), (iii) the RN4220
carrying the empty vector pRMC2 and (iv) RN4220 cells with no vector. The
control treatments (no ciprofloxacin) were (v) the RN4220 cells overexpressing
norA and (vi) the RN4220 cells overexpressing norA supplemented with 33 μM
reserpine. A day before the experiment, overnight cultures were prepared in MH2
broth including 10 µg ml−1 of chloramphenicol for the bacteria carrying vector
pRMC2. The overnight cultures were diluted 1:10 in pre-warmed MH2 broth and
incubated for 2.5–3 h (225 rpm, 37 °C) until they entered an exponential growth
phase. Next, all strains cells were diluted 1:5 times in pre-warmed MH2, the cell
densities were brought to OD595= 0.072 in 100 μl of MH2 (including blank). The
adjusted cultures were diluted 1:1000 using the pre-warmed media corresponding
to their treatments (i.e. with or without 1 mg l−1 ciprofloxacin and with or without
33 µM reserpine) resulting in ~5 × 104 CFUml−1. The cell suspensions were
transferred into pre-warmed 96 deep well plates (Brand, 701340) with 250 µl per
well, sealed with gas-permeable foil and incubated at 225 rpm at 37 °C. Every hour,
six replicate cultures per treatment were sampled, diluted in PBS buffer and plated
to MH2 agar plates. For each time point, new cultures were sampled to avoid
repeated measurements of the same cultures. The agar plates were incubated at
37 °C for 24 h and, then, photographed using a ColonyDoc-It Imaging Station
(UVP, Cambridge, UK). Colonies were counted with ImageJ94 using a custom
script written in ImageJ macro language.
Obtaining spontaneous grlA mutants. Two hundred microliters of several
independent overnight cultures of the S. aureus RN4220 were plated onto MH2
agar plate containing either 1 or 2 mg l−1 ciprofloxacin. Twenty-two colonies were
isolated for DNA extraction and Sanger sequencing to identify resistance muta-
tions. The primers used to amplify known fluoroquinolone resistance regions in
grlA, gyrA, grlB and gyrB genes are listed in Supplementary Table 15. Twenty out of
22 mutants had grlA mutation (one A116P, seven A116E, three E84K, four S80Y
and five S80F). For further characterization, three independently isolated mutants
(i.e., isolated from different overnight cultures) were selected to represent
four resistant mutations (A116E, E84K, S80Y and S80F) resulting in total 12
ciprofloxacin-resistant mutants of RN4220.
Transformation of grlA mutants with pRMC2-norA. Electro-competent cells
were prepared for 12 grlA RN4220 following the protocol from40. The competent
cells were transformed with the pRMC2-norA expression vector. The transfor-
mants were selected on TSB-plates supplemented with 10 µg ml−1 of chlor-
amphenicol and confirmed by PCR and Sanger sequencing (primers are listed in
Supplementary Table 15).
Measuring maximum growth rate of grlA mutants. To estimate the effect of
norA overexpression on growth rate of the grlA mutants, 12 mutants carrying
pRMC2-norA vector and the 12 corresponding parental mutants having no vector
were compared. In addition, the wild-type RN4220 was included as a control (with or
without pRMC2-norA). The mutants were grown overnight in MH2 broth (con-
taining 10 µgml−1 of chloramphenicol wherever necessary for pRMC2-norA selec-
tion). The overnight cultures were diluted 1:1000 in the MH2 broth with 1mg l−1 of
ciprofloxacin and distributed in a 96-well plate with 200 µl of cell suspensions per
well. The assay plates were placed into a Synergy 2 plate reader (BioTek) and
incubated at 37 °C with continuous shaking. The bacterial growth was recorded by
measuring the optical density (λ= 595 nm) every 10 min for minimum 14 h. For
each mutant, six replicate cultures were included, and the experiment was per-
formed in several blocks to accommodate all replicates.
Growth curves were used to estimate the maximum growth rate. A linear
regression was used to calculate a slope for each 5 time-point interval of a growth
curve in a sliding window fashion (by moving a window one time-point and
repeating regression). The resulting distribution of slopes was used to find a
maximum growth rate (corresponding to a maximum change in optical density per
time unit (an hour)). Because the optical density data were log2-transformed prior
the analysis, the obtained estimates should be equivalent to a number of cell
divisions per hour (assuming linear relationship between the optical density and
cell density during the log growth phase).
Measuring resistance to ciprofloxacin of grlA mutants. Twelve grlA mutants
without vector and their corresponding transformants carrying the pRMC2-norA
vector were cultured overnight in MH2 broth. Cultures that contained the vector
were supplemented with 10 mg l−1 chloramphenicol. The next day, cultures were
adjusted to a cell density of 5 × 106 CFUml−1 and inoculated into MH2 medium
containing 13 different doses of ciprofloxacin (0.01–12 mgml−1). After 22 h of
incubation, optical densities were measured using a plate reader. Five replicate
cultures were included per dose/genotype combination. The effect of norA over-
expression was analysed using a dose-response analysis and, additionally, by per-
forming two-sided paired t-test for mean optical densities of mutants obtained at
1 mg l−1 of ciprofloxacin.
Measuring maximum growth rate of strains with norA amplification. To
estimate the effect of norA amplification on fitness, eight parental strains (before
amplification) and eight evolved strains (after amplification) were assayed by
determining maximum growth rate. These assays were performed in the absence of
ciprofloxacin. The parental and evolved strains were grown overnight, diluted
1:1000 in the MH2 broth and inoculated in a 96-well plate (200 µl of cell sus-
pensions per well). The assay plates were incubated inside of a Synergy 2 plate
reader (BioTek) at 37 °C with continuous shaking. The bacterial growth was
recorded by measuring the optical density (λ= 595 nm) every 10 min for mini-
mum 14 h. For each strain, three or four replicate cultures were included. Growth
curves were used to estimate the maximum growth rate by calculate a slope for
each 5 time-point interval of a growth curve in a sliding window fashion. The
maximum slope is equivalent to the number of cell divisions per hour during the
exponential growth phase in the absence of ciprofloxacin. Maximum growth rate in
parental and evolved strains was compared using two-sided paired Wilcoxon sign
rank test.
Statistics and reproducibility. Experimental evolution of 222 strains was repeated
twice. The first attempt failed due to experimental error. Experimental evolution
with cell expressing norA and experimental evolution with norA inhibitor were
performed one time. The transcriptome experiment and fluctuation test were
performed one time. The determination of resistance to ciprofloxacin in 222
parental strains, in 83 evolved populations, in 27 strains with reserpine, and in 12
grlA mutants were performed one time. The experiment with norA overexpression
in RN4220, the killing assay and estimation of growth rates were performed one
time after smaller trial experiments. The results from the trial experiments were
reproducible.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Whole-genome data for 222 parental strains are available from the European Nucleotide
Archive, PRJEB5261. Reference genome sequence of S. aureusMRSA252 is available from
the GeneBank, BX571856.1. Reference genome sequence of S. aureus JP080 is available
from the GeneBank, AP017922.1. Whole-genome sequence data of 122 evolved strains
were deposited at the Sequence Read Archive, BioProject PRJNA633882. RNA sequencing
data for 28 strains are available from Gene Expression Omnibus database, GSE150762.
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Other data that support the findings of this study are available from figshare [https://doi.
org/10.6084/m9.figshare.c.4984364]. Source data are provided with this paper.
Code availability
A Jupyter notebook showing the processing of next-generation sequencing data and a
script used for counting bacterial colonies are available from Gitlab repository [https://
gitlab.com/apson/sa_evolvability/].
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